Nuclear medicine: Proof of principle for targeted drugs in diagnosis and therapy

Current Pharmaceutical Design

Volumn 15, Issue 2, 2009, Pages 173-187

  Leitha, Thomas ^a  

^a DANUBE HOSPITAL   (Austria)

Author keywords

Magic bullet; Molecular imaging; Nuclear medicine; P4 medicine; Targeted therapy; Tracer principle

Indexed keywords

(3 IODOBENZYL)GUANIDINE; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; CAPROMAB PENDETIDE IN 111; FLUORODEOXYGLUCOSE F 18; GANCICLOVIR; GEFITINIB; HYPOXIA INDUCIBLE FACTOR 1; IBRITUMOMAB TIUXETAN; IMATINIB; IODINE 123; IODINE 125; IODINE 131; LUTETIUM 177; MONOCLONAL ANTIBODY; OCTREOTIDE; PENTETREOTIDE; PENTETREOTIDE IN 111; PLACEBO; RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; RHENIUM 186; SAMARIUM 153; SOMATOSTATIN DERIVATIVE; STRONTIUM 89; TECHNETIUM 99M; THALLIUM 201; THYROID HORMONE; TOSITUMOMAB I 131; UNINDEXED DRUG; YTTRIUM 90; TRACER;

ANGIOGENESIS; BLOOD TOXICITY; BONE MARROW DEPRESSION; BONE METASTASIS; BONE SCINTISCANNING; CANCER RADIOTHERAPY; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DNA SYNTHESIS; DOPAMINE UPTAKE; DRUG HALF LIFE; DRUG MEGADOSE; DRUG TARGETING; DRUG WITHDRAWAL; ECHOGRAPHY; GASTROINTESTINAL TUMOR; HEART DISEASE; HEART MUSCLE CELL; HEART SCINTISCANNING; HUMAN; HYPOFERTILITY; INFERTILITY; INTERMETHOD COMPARISON; LIVER METASTASIS; LUNG NON SMALL CELL CANCER; MOLECULAR IMAGING; NEPHROTOXICITY; NERVE CELL DEGENERATION; NEUROBLASTOMA; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUCLEAR MEDICINE; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; RADIOIMMUNOTHERAPY; REVIEW; SALIVARY GLAND DISEASE; SENSITIVITY AND SPECIFICITY; SIGNAL NOISE RATIO; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBSTANTIA NIGRA; SYNOVECTOMY; THYROID CANCER; TREATMENT RESPONSE; X RAY; DRUG DELIVERY SYSTEM; HISTORY; METHODOLOGY; RADIOISOTOPE DIAGNOSIS; RADIOTHERAPY;

DIAGNOSTIC TECHNIQUES, RADIOISOTOPE; DRUG DELIVERY SYSTEMS; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; NUCLEAR MEDICINE; RADIOACTIVE TRACERS; RADIOTHERAPY;

EID: 61549125692     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209787002898     Document Type: Review

References (82)

1. Hood L, Heath JR, Phelps ME, Lin B. Systems biology and new technologies enable predictive and preventative medicine. Science 2004; 306: 640-3
2. Hevesy G. The absorption and translocation of lead by plants: A contribution to the application of the method of radioactive indicators in the investigation of the change of substance in plants. Biochem J 1923; 17: 439-45.
3. Spitzweg C, Morris JC. The sodium iodide symporter: Its pathophysiological and therapeutic implications. Clin Endocrinol 2002; 57: 559-74.
4. Marek K, Innis R, van Dyck C, Fussell B, Early M, Eberly S, et al. [123I]β-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 2001; 57: 2089-94.
5. Cox PH, Belfer AJ, van der Pompe WB. Thallium 201 chloride uptake in tumours, a possible complication in heart scintigraphy. BJR 1976; 49: 767-8.
6. Anger H. A new instrument for mapping gamma-ray emitters. Biol Med Quarterly Report UCRL 1957; 3653: 38.
7. Kuhl DE, Edwards RQ. Reorganizing data from transverse section scans of the brain using digital processing. Radiology 1968; 91: 975-83.
8. Ter-Pogossian MM, Phelps ME, Hoffman EJ, Mullani NA. A positron- emission transaxial tomograph for nuclear imaging (PETT). Radiology 1975; 114: 89-98.
9. Bauer GCH, Wendeberg B. External counting of Ca-47 and Sr-85 in studies of localized lesions in man. J Bone Joint Surg Br 1959; 41B: 558-60.
10. Subramanian G, McAfee JG, Blair RJ, Mehter A, Connor T. 99m Tc-EHDP: A potential radiopharmaceutical for skeletal imaging. J Nucl Med 1972; 13: 947-50.
11. Krebs HA. Otto Heinrich Warburg, 1883-1970. Biogr Mem Fellows R Soc 1972; 18: 629-99.
12. Tewson TJ, Welch MJ, Raichle ME. [18F]-labeled 3-deoxy-3-fluoro-D-glucose: Synthesis and preliminary biodistribution data. J Nucl Med 1978; 19:1339-45.
13. Patz EF Jr, Lowe VJ, Hoffman JM, Paine SS, Burrowes P, Coleman RE, et al. Focal pulmonary abnormalities: Evaluation with F- 18 fluorodeoxyglucose PET scanning. Radiology 1993; 188: 487-90.
14. Mankoff DE. A definition of molecular imaging. J Nucl Med 2007; 48: 18-21N.
15. Margolis DJ, Hoffman JM, Herfkens RJ, Jeffrey RB, Quon A, Gambhir SS. Molecular imaging techniques in body imaging. Radiology 2007; 245: 333-56.
16. Townsend DW. Multimodality imaging of structure and function. Phys Med Biol 2008; 53: R1-39.
17. Slomka PJ. Software approach to merging molecular with anatomic information. J Nucl Med 2004; 45(Suppl 1): 36S-45.
18. Blankenberg FG, Katsikis PD, Tait JF, Davis RE, Naumovski L, Ohtsuki K, et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Natl Acad Sci USA 1998; 95: 6349-54.
19. Boersma HH, Kietselaer BL, Stolk LM, Bennaghmouch A, Hofstra L, Narula J, et al. Past, present, and future of annexin A5: From protein discovery to clinical applications. J Nucl Med 2005; 46: 2035-50.
20. Tillisch J, Brunken R, Marshall R, Schwaiger M, Mandelkern M, Phelps M, et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 1986; 314: 884-8.
21. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, et al. Imaging proliferation in vivo with [F- 18]FLT and positron emission tomography (PET). Nat Med 1998; 4: 1334-6.
22. Gambhir SS, Barrio JR, Wu L, Iyer M, Namavari M, Satyamurthy N, et al. Imaging of adenoviral-directed herpes simplex virus Type 1 thymidine kinase reporter gene expression in mice with radiolabeled ganciclovir. J Nucl Med 1998; 39: 2003-11.
23. Massoud TF, Singh A, Gambhir SS. Nonivasive Molecular Neuroimaging using reporter genes: Part 1, principles revisited. Am J Neuroradiol 2008; 29: 229-34.
24. Massoud TF, Singh A, Gambhir SS. Nonivasive molecular neuroimaging using reporter genes: Part 2, experimental, current and future applications. Am J Neuroradiol 2008; 29: 409-18.
25. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: Role of the HIF system. Nat Med 2003; 9: 677-84.
26. Piert M, Machulla HJ, Becker G, Aldinger P, Winter E, Bares R. Dependency of the [18F] fluoromisonidazole uptake on oxygen delivery and tissue oxygenation in the porcine liver. Nucl Med Biol 2000; 27: 693-700.
27. Rajendran JG, Krohn KA. Imaging hypoxia and angiogenesis in tumors. Radiol Clin North Am 2005; 43: 169-87.
28. Yearn Seong Choe YS, Lee KH. Targeted in vivo imaging of angiogenesis: Present status and perspectives. Curr Pharm Des 2007; 13, 17-31.
29. Thorwarth D, Eschmann SM, Holzner F, Paulsen F, Alber M. Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. Radiother Oncol 2006; 80: 151-6.
30. Bache M, Kappler M, Said HM, Staab A, Vordermark D. Detection and specific targeting of hypoxic regions within solid tumors: Current preclinical and clinical strategies. Curr Med Chem 2008; 15: 322-38
31. Kostakoglu L, Goldsmith SJ. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J Nucl Med 2003; 44: 224-39.
32. Piwnica-Worms D, Kesarwala AH, Pichler A, Prior JL, Sharma V. Single photon emission computed tomography and positron emission tomography imaging of multi-drug resistant p-glycoprotein-monitoring a transport activity important in cancer, blood-brain barrier function and Alzheimer's disease. Neuroimaging Clin N Am 2006; 16: 575-89.
33. Bodei L, Kassis AI, Adelstein SJ, Mariani G. Radionuclide therapy with iodine-125 and other auger-electron-emitting radionuclides: Experimental models and clinical applications. Cancer Biother Radiopharm 2003; 18: 861-77.
34. Boswell CA, Brechbiel MW. Auger Electrons: Lethal, low Energy, and coming soon to a tumor cell nucleus near you. J Nucl Med 2005; 12: 1946-47.
35. EANM Procedure Guidelines for Radiosynovectomy: http://eanm.org/ scientific_info/guidelines/gl_radio_synovectomy.pdf (2nd October 2008).
36. Oyen WJG, Bodei L, Giammarile F, Maecke HR, Tennvall J, Luster M, et al. Targeted therapy in nuclear medicine - current status and future prospects. Ann Oncol 2007; 18: 1782-92.
37. Dohán O, De la Vieja A, Paroder V, Riedel C, Artani M, Reed M, et al. The sodium/iodide symporter (NIS): Characterization, regulation, and medical significance. Endocr Rev 2003; 24: 48-77.
38. Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer 2003; 89: 1638-44.
39. Luster M, Lippi F, Jarzab B, Perros P, Lassmann M, Reiners C, et al. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: A comprehensive review. Endocr Relat Cancer 2005; 12: 49-64.
40. Haugen BR. Redifferentiation therapy in advanced thyroid cancer. Curr Drug Targets Immune Endocr Metabol Disord 2004; 4: 175-80.
41. Dadachova E, Carrasco N. The Na/I symporter (NIS): Imaging and therapeutic applications. Semin Nucl Med 2004; 34: 23-31.
42. Lewington VJ. Targeted radionuclide therapy for bone metastases. Eur J Nucl Med 1993; 20: 66-74.
43. Lewington VJ. Bone-seeking radionuclides for therapy. J Nucl Med 2005; 46: 38-47.
44. Pecher C. Biological investigations with radioactive calcium and strontium. Preliminary report on the use of radioactive strontium in the treatment of metastatic bone cancer. Univ California Publications Pharmacol 1942; 2: 117-49.
45. Lewington VJ, McEwan AJ, Ackery DM, Bayty RJ, Keeling DH, Macleod PM, et al. A prospective randomised double blind corssover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 1991; 27: 954-8.
46. Nakajo M, Shapiro B, Copp J, Kalff V, Gross MD, Sisson JC, et al. The normal and abnormal distribution of the adrenomedullary imaging agent m[I-131]iodobenzylguanidine (I-131 MIBG) in man: Evaluation by scintigraphy. J Nucl Med 1983; 24: 672-82.
47. Kinnier-Wilson LM, Draper GJ. Neuroblastoma, its natural history and prognosis: A study of 487 cases. Br Med J 1974; 3: 301-7.
48. Hoefnagel CA, Voute PA, DeKraker J, Marcuse HR. Radionuclide diagnosis and therapy of neural crest tumors using iodine-131 MIBG. J Nucl Med 1987; 28: 308-14.
49. Mastrangelo S, Tornesello A, Diociaiuti L, Pession A, Prete A, Rufini V, et al. Treatment of advanced neuroblastoma: Feasibility and therapeutic potential of a novel approach combining 131-IMIBG and multiple drug chemotherapy. Br J Cancer 2001; 84: 460-4.
50. Reubi JC, Waser B, Schaer JC, Laissue. Somatostatin receptor sst1- sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001; 28: 836-46.
51. Krulich L, Dhariwal AP, McCann SM. Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. Endocrinology 1968; 83: 783-90.
52. Guillemin R. Brazeau P, Bohlen P, Esch F, Ling N, Wehrenberg WB. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science 1982; 218: 585-7.
53. Rivier J, Spiess J, Thorner M, Vale W. Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour. Nature 1982; 300: 276-8.
54. Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, et al. SMS 201-995: A very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982; 31: 1133-40.
55. Reubi JC. New specific radioligand for one subpopulation of brain somatostatin receptors. Life Sci 1985; 36: 1829-36.
56. Krenning EP, Bakker WH, Breeman WA, Koper JW, Kooij PP, Ausema L, et al. Localization of endocrine related tumours with radioiodinated analogue of somatostatin. Lancet 1989; 1: 242-4.
57. Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, et al. Radiolabeled somatostatin analog 177Lu-DOTA0,Tyr3octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005; 23: 2754-62.
58. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-7.
59. Goldenberg DM, DeLand FH: History and status of tumor imaging with radiolabeled antibodies. J Biol Resp Modif 1982; 1:121-36.
60. Fischman AJ, Khaw BA, Strauss HW. Quo vadis radioimmune imaging. J Nucl Med 1989; 30: 1911-5.
61. Dorfman NA. The optimal technological approach to the development of human hybridomas. J Bol Resp Med 1985; 4: 213-39.
62. Keane TE, Rosner IL, WingoMS, McLeod DG. The Emergence of Radioimmunoscintigraphy for Prostate Cancer. Rev Urol 2006; 8: 20-8.
63. Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard J, Fehrenbacher L, et al. Pivotal study of iodine I-131 tositumomab for chemotherapy-refractory low-grade or transformed B-cell non- Hodgkin's lymphomas. J Clin Oncol 2001; 19: 3918-28.
64. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 2453-63.
65. Boerman OC, van Schaijk FG, Oyen WJG, Corstens FHM. Pretargeted radioimmunotherapy of cancer: Progress step by step. J Nucl Med 2003; 44: 400-11
66. Paganelli G, Riva P, Deleide G, Clivio A, Chiolerio F, Scassellati GA, et al. In vivo labelling of biotinylated monoclonal antibodies by radioactive avidin: A strategy to increase tumor radiolocalization. Int J Cancer Suppl 1988; 2: 121-5.
67. Axworthy DB, Reno JM, Hylarides MD, Mallet RW, Theodore LJ, Gustauson LM, et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci USA 2000; 97: 1802-07.
68. Boerman OC, Kranenborg MH, Oosterwijk E, Griffiths GL, McBride WJ, Oyen WJ, et al. Pretargeting of renal cell carcinoma: Improved tumor targeting with a bivalent chelate. Cancer Res 1999; 59: 4400-05.
69. Chatal JF, Campion L, Kraeber-Bodéré F, Bardet S, Vuillez JP, Charbonnel B, et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anticarcinoembryonic- antigen radioimmunotherapy: A collaborative study with the French Endocrine Tumor Group. J Clin Oncol 2006; 24: 1705-11.
70. DeNardo SJ. Radioimmunodetection and therapy of breast cancer. Semin Nuc Med 2005; 35: 143-51.
71. Verheijen RH, Massuger LF, Benigno BB, Epenetos AA, Lopes A, Soper JT, et al. Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncol 2006; 24: 571-8.
72. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
73. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
74. Ratain MJ. Phase II oncology trials: Let's be positive. Clin Cancer Res 2005; 11: 5661-2.
75. Goffin J, Baral S, Tu D, Nomikos D, Seymour L. Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval. Clin Cancer Res. 2005; 11: 5928-34.
76. Wolfgang A. Weber WA, Figlin R. Monitoring cancer treatment with PET/CT: Does it make a difference? J Nucl Med 2007; 48: 36-44
77. Antoch G, Kanja J, Bauer S, Kuehl H, Renzing-Koehler K, Schuette J, et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 2004; 45: 357-65.
78. Su H, Bodenstein C, Dumont RA, Seimbille Y, Dubinett S, Phelps ME, Herschman H, et al. Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res 2006; 12: 5659-67.
79. Su H, Seimbille Y, Ferl GZ, Bodenstein C, Fueger B, Kim KJ, et al. Evaluation of (18)Fgefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors. Eur J Nucl Med Mol Imaging 2008; 35:1089-99.
80. Chakravarty R, Pandey U, Manolkar RB, Dash A, Venkatesh M, Pillai MR. Development of an electrochemical 90 Sr-90 Y generator for separation of 90 Y suitable for targeted therapy. Nucl Med Biol 2008; 35(2): 245-53.
81. Hamoudeh M, Kamleh MA, Diab R, Fessi H. Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer. Adv Drug Deliv Rev 2008; 60(12): 1329-46.
82. Kersemans V, Kersemans K, Cornelissen B. Cell penetrating peptides for in vivo molecular imaging applications. Curr Pharm Des 2008; 14(24): 2415-47.